Internal Medicine
WHO: COVID-19 pandemic triggers a 25% increase in the prevalence of anxiety and depression worldwide.
3 Mar, 2022 | 09:44h | UTCNews Release: COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide – World Health Organization
Scientific Brief: Mental health and COVID-19: Early evidence of the pandemic’s impact – World Health Organization
Commentary on Twitter (thread – click for more)
? #COVID19 pandemic triggers 25% increase in prevalence of anxiety & depression worldwide: New WHO publication
More: https://t.co/QFiH7j312f#MentalHealth?: Getty Images/J. Paget pic.twitter.com/iX15sbHXcW
— World Health Organization (WHO) (@WHO) March 2, 2022
[News release – not published yet] Study finds blood pressure cuff size matters, affects blood pressure readings.
3 Mar, 2022 | 08:47h | UTCStudy finds blood pressure cuff size matters, affects blood pressure readings – AHA Newsroom
M-A: Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19.
3 Mar, 2022 | 08:49h | UTCEditorial: Treatment of severe covid-19 with interleukin 6 receptor inhibition – BMJ Medicine
Related study (just published): Mortality Rates Among Hospitalized Patients With COVID-19 Infection Treated With Tocilizumab and Corticosteroids: A Bayesian Reanalysis of a Previous Meta-analysis – JAMA Network Open
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations.
3 Mar, 2022 | 08:46h | UTC
Commentary on Twitter
Our latest #Review is online now. #COVID-19 risks, outcomes and treatment considerations in #rheumatic disease.
Read it for #free here: https://t.co/WsmuyoFNGT@philipcrobinson pic.twitter.com/I4RWh0Gftr
— NatRevRheumatol (@NatRevRheumatol) February 28, 2022
RCT: In patients with acute coronary syndrome, clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy was NOT noninferior to 12 months of dual antiplatelet therapy.
3 Mar, 2022 | 08:32h | UTCComparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial – JAMA Cardiology (free for a limited period)
Commentary on Twitter
Study found the effectiveness of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy is inconclusive, and further investigation is needed to define the optimal therapy for patients with acute coronary syndromes. https://t.co/aqxk39TjY3
— JAMA Cardiology (@JAMACardio) March 2, 2022
A low-energy diet shows promise for reducing the symptoms of fibromyalgia.
3 Mar, 2022 | 08:23h | UTCEarly Relationships of a Low-Energy Diet With Symptoms of Fibromyalgia ACR Open Rheumatology
Commentary: Fibromyalgia Patients See Rapid Benefit From Low-Cal Diet — With marked symptom reduction in just 3 weeks, weight loss not a factor – MedPage Today (free registration required)
The effects of foods on LDL cholesterol levels: A systematic review of the accumulated evidence from systematic reviews and meta-analyses of randomized controlled trials.
3 Mar, 2022 | 08:22h | UTC
Cancer risks other than female breast and ovarian cancers associated with BRCA1 and BRCA2 pathogenic variants.
3 Mar, 2022 | 08:14h | UTCCancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants – Journal of Clinical Oncology
Commentary: Faulty BRCA genes linked to prostate and pancreatic cancers – University of Cambridge
Coccidioidomycosis: A Contemporary review.
3 Mar, 2022 | 08:20h | UTCCoccidioidomycosis: A Contemporary Review – Infectious Diseases and Therapy
Meta-analysis showed a 2.4-fold increased risk of cancer in patients with pediatric-onset inflammatory bowel disease.
3 Mar, 2022 | 08:06h | UTCCommentary: Kids With IBD Need Close Monitoring as They Grow Up — Meta-analysis confirms: substantially increased cancer risk in adulthood – MedPage Today (free registration required)
Concise Review: A Practical 5-step approach to nausea and vomiting.
3 Mar, 2022 | 08:04h | UTCA Practical 5-Step Approach to Nausea and Vomiting – Mayo Clinic Proceedings
M-A: Evaluation of budesonide-formoterol for maintenance and reliever therapy among patients with poorly controlled asthma.
3 Mar, 2022 | 07:59h | UTC
Erosive hand osteoarthritis: latest findings and outlook.
3 Mar, 2022 | 08:01h | UTCErosive hand osteoarthritis: latest findings and outlook – Nature Reviews Rheumatology (if the link is paywalled, try this one)
Commentary on Twitter
#MarchIssue | Read our #Review on the clinical features and risk factors of erosive hand #osteoarthritis (an aggressive condition with poor outcomes), and progress in biomarkers, imaging, classification and treatmenthttps://t.co/GSvgnXYYPS pic.twitter.com/PSzeucO0cH
— NatRevRheumatol (@NatRevRheumatol) February 28, 2022
Prescribing Nirmatrelvir–Ritonavir for Covid-19: How to recognize and manage drug–drug interactions.
2 Mar, 2022 | 09:01h | UTCRelated:
Pfizer antiviral pills may be risky with other medications – NBC News
Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.
2 Mar, 2022 | 09:03h | UTCCommentary: Review of Anticoagulation in Patients With COVID-19: Key Points – American College of Cardiology
NICE Guideline: Mental wellbeing at work.
2 Mar, 2022 | 08:57h | UTCMental wellbeing at work – National Institute for Health and Care Excellence
Review: Diagnosis and treatment of pulmonary sarcoidosis.
2 Mar, 2022 | 08:50h | UTCDiagnosis and Treatment of Pulmonary Sarcoidosis: A Review – JAMA (free for a limited period)
Related:
ERS clinical practice guidelines on treatment of sarcoidosis.
ATS Guideline: Diagnosis and Detection of Sarcoidosis
WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension.
Sarcoidosis: A clinical overview from symptoms to diagnosis.
Clinical Manifestations, Diagnosis, and Treatment of Sarcoidosis
Systematic Review: Postcholecystectomy diarrhea rate and predictive factors.
2 Mar, 2022 | 08:48h | UTC
The management of diabetic ketoacidosis in adults—An updated guideline from the Joint British Diabetes Society for Inpatient Care.
1 Mar, 2022 | 09:00h | UTC
M-A: Survival for waitlisted kidney failure patients receiving transplantation vs. remaining on waiting list.
2 Mar, 2022 | 08:46h | UTC
Guideline Update: Timing of elective surgery and risk assessment after SARS-CoV-2 infection – “The guidance remains that patients should avoid elective surgery within 7 weeks of infection, unless the benefits of doing so exceed the risk of waiting”.
1 Mar, 2022 | 08:58h | UTCTiming of elective surgery and risk assessment after SARS-CoV-2 infection: an update – Anaesthesia
Related:
Guideline: SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery
BJS commission on surgery and perioperative care post-COVID-19.
ASA Guidance: Preoperative testing for COVID-19 is essential, regardless of vaccination.
Position statement: Perioperative management of post-COVID-19 surgical patients.
Systematic review on inappropriate use of clinical practices in Canada identified 144 underused practices, 109 overused practices, and 25 practices that were both under- and overused.
1 Mar, 2022 | 08:52h | UTCNews Release: Inappropriate use of 228 clinical practices in Canada – Canadian Medical Association Journal
RCT: Prophylactic melatonin does not reduce the incidence of delirium in intensive care patients.
1 Mar, 2022 | 08:45h | UTCProphylactic melatonin for delirium in intensive care (Pro-MEDIC): a randomized controlled trial – Intensive Care Medicine (link to abstract – $ for full-text)
Commentaries on Twitter
Enteral prophylactic melatonin initiated early (within 48h of admission) & continued throughout #ICU (MAX 14 consecutive days) do not ⬇️#delirium prevalence vs placebo, Pro-MEDIC multicentre RCT
➡️12??ICUs
➡️841 pts
➡️delirium-free assessments 79.2% vs 80%https://t.co/Gt5o1VuRo7 pic.twitter.com/gPRWxxmhHS— Intensive Care Medicine (@yourICM) February 28, 2022
In 841 ICU patients with expected stay >72h, 4 mg melatonin within 48h after admission for 14 days vs placebo made no sign. differences in delirium-free assessments, LoS, 90d mortality, nor quality & quantity of sleep
Good bye Melatonin, we had a good timehttps://t.co/d0dayil99W— Peter Nydahl (@NydahlPeter) February 28, 2022
RCT: A mindfulness-oriented intervention may reduce opioid misuse and chronic pain in primary care.
1 Mar, 2022 | 08:32h | UTCMindfulness-Oriented Recovery Enhancement vs Supportive Group Therapy for Co-occurring Opioid Misuse and Chronic Pain in Primary Care: A Randomized Clinical Trial – JAMA Internal Medicine (link to abstract – $ for full-text)
Commentary: Mindfulness-Based Intervention Found to Reduce Chronic Pain and Opioid Misuse – Psychiatric News Alert
Commentary on Twitter
A randomized clinical trial showed that #Mindfulness-Oriented Recovery Enhancement delivered in the primary care setting reduces opioid misuse by as much as 46%, while simultaneously reducing chronic pain and emotional distress. https://t.co/eNj42RBCRA @DrEricGarland pic.twitter.com/tBatMT9lkQ
— JAMA Internal Medicine (@JAMAInternalMed) February 28, 2022
Review: New generation psychological treatments in chronic pain.
1 Mar, 2022 | 08:41h | UTCNew generation psychological treatments in chronic pain – The BMJ (free for a limited period)